Valniche is a brand of Valganciclovir, a pro-drug of gancilcovir which, after oral administration, is rapidly converted to ganciclovir by intestinal and hepatic esterases. The virustatic activity of ganciclovir is due to inhibition of viral DNA synthesis by: (a) competitive inhibition of incorporation of deoxyguanosine-triphosphate into DNA by viral DNA polymerase, and (b) incorporation of ganciclovir triphosphate into viral DNA causing termination of, or very limited, further viral DNA elongation. For kidney transplant patients, the recommended dose is 900 mg once daily with food, starting within 10 days of transplantation until 200 days post-transplantation.

Product Active Ingredient(s) Strength Features Dosage Form
VALNICHE • Valganciclovir 450 mg • Rapidly and extensively converted to the active ingredient ganciclovir
• Bioavailability is 10-fold higher than from oral gancilcovir
  • VALNICHE is indicated for the prophylaxis of cytomegalovirus (CMV) infection and disease following solid organ transplantation in patients at risk of CMV disease.
  • Treatment of CMV Retinitis in AIDS
  • Blood: neutropenia, anemia, low platelets. Myelosuppression is one of the main side effects that may limit prolonged use of valganciclovir.
  • Gastrointestinal: diarrhea, nausea, vomiting, abdominal pain.
  • Central nervous system: fever, headache, insomnia, paresthesia, and peripheral neuropathy.
  • Ocular: retinal detachment


Copyright © 2013 - Alniche Life Sciences Pvt. Ltd. | All Rights Reserved

Disclaimer: The information provided herein is not medical advice and is not intended to replace medical advice offered by a health care provider. Please consult your health care provider for advice.